申请人:Rozas Hernando Maria Isabel
公开号:US20100331384A1
公开(公告)日:2010-12-30
The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into α and β subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has been implicated in the pathophysiology of a number of diseases. Disclosed herein are a series of novel guanidine and 2-aminoimidazoline compounds which are ligands of the alpha2-adrenoceptor (α2-ARs) subclass of adrenergic receptors. The invention also provides for pharmaceutical compositions comprising the novel compounds. The compounds are suitable for use in the manufacture of medicaments for the treatment of α2-ARs associated disorders, such as depression, schizophrenia, glaucoma and analgesia.
肾上腺素受体或肾上腺素受体是一类G蛋白偶联受体家族,分为α和β亚类。肾上腺素受体在调节多种生理条件中起着重要作用,其功能失调已被认为与多种疾病的病理生理有关。本文披露了一系列新型胍啶和2-氨基咪唑啉化合物,它们是肾上腺素受体的α2-亚型(α2-ARs)亚类的配体。该发明还提供了包含这些新型化合物的药物组合物。这些化合物适用于制造用于治疗与α2-ARs相关疾病的药物,如抑郁症、精神分裂症、青光眼和镇痛的药物。